STOCKHOLM, Sweden, Nov. 5, 2004 (PRIMEZONE) -- Artimplant:
- Artimplant's net sales for the 9 month period reached SEK 1.1 million (SEK 1.2 million)
- Losses after tax amounted to SEK -22.4 million (SEK -21.0 million)
- The result per share amounted to SEK -0.59 (SEK -0.97)
- FDA clearance through a 510(k) for Artelon(R) CMC-I Spacer
DEVELOPMENTS AFTER THE END OF THE PERIOD
- Development cooperation between Artimplant and Molnlycke Health Care terminated
Forthcoming financial reports: Release of year end results: February, 17, 2005 Shareholders annual general meeting: April 20, 2005, at 4:00 PM in Artimplant's HQ Report for the first quarter 2005: April 20, 2005
Financial reports are available at www.artimplant.se at the same time that they're distributed to the media. For information regarding business model, technology and products see Artimplant's Annual Report 2003, which is available at our web site.
ARTIMPLANT
Artimplant's mission is to develop novel biodegradable materials and implants that meet the needs of patients, physicians and healthcare providers in orthopedics and other therapy areas.
The company works together with global partners as a center of excellence in this development. Artimplant's vision is to become the partner of choice in biomaterials for hard and soft tissue repair in multiple therapy areas.
Artimplant is a public company, listed on the Stockholm Exchange, O-list.
Nota Bene: Artelon(R) is a registered trade name in Europe, the United States and Japan.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
The full report:
http://www.waymaker.net/bitonline/2004/11/05/20041105BIT20130/wkr0001.pdf